Business & Regulation

Where did DNDi come from – and where is it going? We ask the nonprofit organization’s chief for a rundown

Clinical trials? Cancer R&D? AstraZeneca’s Matthew Ellis shares his views on the future of pharma.

How we can begin overcoming patients’ fears and misconceptions of cell and gene therapy

Can AI help us better understand and define chronic pain?

How AI can be leveraged to improve patient acquisition.

Explore the potential of AI with industry experts.

Disruptive technologies are often talked about in pharma circles. But when it comes to AI, what long-term impact will it have?

Our animated chart illustrates Pfizer’s changing fortunes – and the significant contribution its COVID-19 efforts have made to revenues.

The world wasn’t ready for COVID-19. But if we learn the right lessons, next time next time we’ll do better.

To see true progress, pharma manufacturers will have to do away with their legacy systems.